secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2023-07-10T23:59:59+00:00
Accession:  0001193125-23-184748
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum licenses CAMP4's Diamond Blackfan Anemia program for up to $70M in milestones plus royalties
--------------------------------------------------------------------------------

- Exclusive worldwide license to CAMP4's DBA program, including small molecule compounds and patent rights.
- Undisclosed upfront payment; up to $35M in development/regulatory milestones and $35M in sales milestones.
- Royalties on net sales: mid-single to low-double digit, subject to reductions for patent loss or generics.
- Fulcrum responsible for all development and regulatory costs; CAMP4 may terminate for non-payment or patent challenges.
- License expires per product/country upon later of patent expiry, regulatory exclusivity end, or 10 years after first sale.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000119312523184748/0001193125-23-184748-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000119312523184748/d443448d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-184748

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer